Delving into the Latest Updates on The Second Hospital of Shandong University with Synapse

Overview

Tags

Neoplasms

Immune System Diseases

Hemic and Lymphatic Diseases

CAR-T

CAR-NK

Mesenchymal stem cell therapy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	5
Immune System Diseases	4
Hemic and Lymphatic Diseases	3

Top 5 Drug Type	Count

CAR-T	4
CAR-NK	2
Small molecule drug	1
Mesenchymal stem cell therapy	1

Top 5 Target	Count

CD19(B-lymphocyte antigen CD19)	2
CD38(Lymphocyte differentiation antigen CD38)	1
IL-1RA(interleukin 1 receptor antagonist)	1
CD38 x SLAMF7	1
PAK4 x PAK5	1

Gastric cancer remains one of the deadliest cancers globally due to delayed detection and limited treatment options, underscoring the critical need for innovative prognostic methods. Disulfidptosis, a recently discovered programmed cell death triggered by disulphide stress, presents a fresh avenue for therapeutic exploration. This research examines disulfidptosis-related long noncoding RNAs (DRLs) in gastric cancer, with the goal of leveraging these lncRNAs as potential markers to enhance patient outcomes and treatment approaches. Comprehensive genomic and clinical data from stomach adenocarcinoma (STAD) were obtained from The Cancer Genome Atlas (TCGA). Employing least absolute shrinkage and selection operator (LASSO) regression analysis, a prognostic model was devised incorporating five key DRLs to forecast survival rates. The effectiveness of this model was validated using Kaplan-Meier survival plots, receiver operating characteristic (ROC) curves, and extensive functional enrichment studies. The importance of select lncRNAs and the expression variability of genes tied to disulfidptosis were validated via quantitative real-time PCR (qRT-PCR) and Western blot tests, establishing a solid foundation for their prognostic utility. Analyses of functional enrichment and tumour mutation burden highlighted the biological importance of these DRLs, connecting them to critical cancer pathways and immune responses. These discoveries broaden our comprehension of the molecular framework of gastric cancer and bolster the development of tailored treatment plans, highlighting the substantial role of DRLs in clinical prognosis and therapeutic intervention.

31 Dec 2025·Redox Report

Oxidative stress and reactive oxygen species in otorhinolaryngological diseases: insights from pathophysiology to targeted antioxidant therapies

Review

Author: Liu, Shengyang ; Yu, Jinzhuang ; Tu, Yanyi ; Li, Ping ; Meng, Linghui ; Li, Tao ; Luo, Jinfeng ; Shi, Li

Oxidative stress, characterized by an imbalance between excessive reactive oxygen species (ROS) production and impaired antioxidant defenses, is closely linked to the pathogenesis of various otorhinolaryngological disorders. Mitochondria, as the primary site of cellular energy production, play a crucial role in modulating oxidative stress. Mitochondrial dysfunction exacerbates ROS generation, leading to cellular damage and inflammatory responses. In otorhinolaryngological diseases, oxidative stress is strongly associated with conditions such as hearing loss, allergic rhinitis, and chronic sinusitis, where oxidative damage and tissue inflammation are key pathological features. Recent studies have highlighted the potential of antioxidant therapies to mitigate oxidative stress and restore homeostasis, offering promising avenues for alleviating symptoms in these diseases. However, despite the encouraging results from early-stage research, the clinical efficacy of antioxidant interventions remains to be fully established. This review provides an overview of the role of oxidative stress in otorhinolaryngological diseases and evaluates the therapeutic potential of antioxidant strategies.

01 Oct 2025·Biomaterials

Multifunctional albumin-based hydrogel/microglia composites enhancing the therapeutic potential of neonatal microglia in complex spinal cord injuries and sealing dural rupture

Article

Author: Jiang, Yanyan ; Li, Mingxin ; Ning, Bin ; Guo, Yijian ; Zhou, Xiaoyu ; Zhang, Qingchen ; Li, Can ; Hong, Yatian ; Li, Shang

Treatment for spinal cord injuries (SCIs) remains largely ineffective, with scar formation and neural degeneration being major barriers to functional recovery. Neonatal microglia have shown potential in reducing scar formation and promoting axonal regrowth. However, cell viability and retention at the injury site are often suboptimal. The hostile post-SCI inflammatory microenvironment leads to poor cell survival and the dural damage that is frequently associated with SCIs results in cell loss. To address these challenges, we have developed an albumin-based hydrogel. This hydrogel creates a favorable microenvironment for the encapsulated cells, mimicking the extracellular matrix and enhancing the viability of the transplanted cells. In vivo studies demonstrate its efficacy in preventing scar formation, promoting axonal regeneration, and sealing the dura. Importantly, this hydrogel leverages albumin, a natural polymer in the body, and is synthesized through a simple process, making it highly feasible for clinical translation. In summary, this albumin hydrogel is a valuable delivery vehicle that enhances the therapeutic potential of neonatal microglia in treating SCIs, particularly those involving dural rupture.

100 Deals associated with The Second Hospital of Shandong University

Login to view more data

100 Translational Medicine associated with The Second Hospital of Shandong University

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 09 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

1

Preclinical

Phase 1 Clinical

5

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

CD19 CAR-T Cells(The Second Hospital of Shandong University) ( CD19 )	B-Cell Lymphoma More	Phase 1 Clinical
CD38/CS1 Chimeric Antigen Receptor T Cell(The Second Hospital of Shandong University) ( CD38 x SLAMF7 )	-	Phase 1 Clinical
CAR-NK Cells(The Second Hospital of Shandong University)	Relapsed Solid Neoplasm More	Phase 1 Clinical
CAR-T Cells(The Second Hospital of Shandong University)	Relapsed Solid Neoplasm More	Phase 1 Clinical
CD19 CAR-NK Cells(The Second Hospital of Shandong University) ( CD19 )	B-Cell Lymphoma More	Phase 1 Clinical